Dr. Daniel F. Hanley presented the results of the MISTIE Phase II trial today at the International Stroke Conference (ISC) in New Orleans. A copy of the abstract, presentation slides and the video are available in this article (click CONTINUE READING for the full article). Also, be sure to see Gayane Yenokyan's recent presentation to the CLEAR III investigators and coordinators on the preliminary outcomes data.
MISTIE Phase II Results: Safety, Efficacy and Surgical Performance
Background: We report the primary clinical outcome results (180 day mRS) for the “Minimally Invasive Surgery plus t-PA for Intracerebral Hemorrhage Evacuation” (MISTIE) trial, a NINDS-funded, two-stage, study of safety, efficacy, and surgical performance that continued to completion after a planned interim analysis showed a strong indication of safety, and efficacy.